Stock Track | BeiGene Soars Nearly 7% as Company Forecasts Positive Operating Income for 2025

Stock Track

Jan 14

Shares of BeiGene Ltd. (HKG:6160, SHA:688235) surged nearly 7% in pre-market trading on Tuesday, after the biopharmaceutical company announced that it expects to achieve positive operating income for the full year 2025 in accordance with US GAAP (Generally Accepted Accounting Principles).

The encouraging forecast from BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative cancer medicines, sent a positive signal to investors and sparked a rally in the company's stock. Shares were up 4% in Hong Kong and 4% in Shanghai during Tuesday morning trading session.

BeiGene's projection of positive operating income for 2025 reflects the company's progress and growth prospects in the oncology market. As a leading player in the development of innovative cancer treatments, the company's strong financial performance and positive outlook have fueled investor confidence, driving the stock's upward momentum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125115215"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125115215\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125115215?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125115215","market":"us","top_or_hot":-1,"title":"Stock Track | BeiGene Soars Nearly 7% as Company Forecasts Positive Operating Income for 2025","media":"Stock Track","content":"<p>Shares of BeiGene Ltd. (HKG:6160, SHA:688235) surged nearly 7% in pre-market trading on Tuesday, after the biopharmaceutical company announced that it expects to achieve positive operating income for the full year 2025 in accordance with US GAAP (Generally Accepted Accounting Principles).</p>\n\n<p>The encouraging forecast from BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative cancer medicines, sent a positive signal to investors and sparked a rally in the company's stock. Shares were up 4% in Hong Kong and 4% in Shanghai during Tuesday morning trading session.</p>\n\n<p>BeiGene's projection of positive operating income for 2025 reflects the company's progress and growth prospects in the oncology market. As a leading player in the development of innovative cancer treatments, the company's strong financial performance and positive outlook have fueled investor confidence, driving the stock's upward momentum.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeiGene Soars Nearly 7% as Company Forecasts Positive Operating Income for 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeiGene Soars Nearly 7% as Company Forecasts Positive Operating Income for 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-14 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of BeiGene Ltd. (HKG:6160, SHA:688235) surged nearly 7% in pre-market trading on Tuesday, after the biopharmaceutical company announced that it expects to achieve positive operating income for the full year 2025 in accordance with US GAAP (Generally Accepted Accounting Principles).</p>\n\n<p>The encouraging forecast from BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative cancer medicines, sent a positive signal to investors and sparked a rally in the company's stock. Shares were up 4% in Hong Kong and 4% in Shanghai during Tuesday morning trading session.</p>\n\n<p>BeiGene's projection of positive operating income for 2025 reflects the company's progress and growth prospects in the oncology market. As a leading player in the development of innovative cancer treatments, the company's strong financial performance and positive outlook have fueled investor confidence, driving the stock's upward momentum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1125115215","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125115215","pubTimestamp":1736819427,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of BeiGene Ltd.  surged nearly 7% in pre-market trading on Tuesday, after the biopharmaceutical company announced that it expects to achieve positive operating income for the full year 2025 in accordance with US GAAP .The encouraging forecast from BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative cancer medicines, sent a positive signal to investors and sparked a rally in the company's stock. Shares were up 4% in Hong Kong and 4% in Sha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"股票赛道百济神州飙升近7%，公司预测2025年营业收入为正","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"Shares of BeiGene Ltd. (HKG:6160, SHA:688235) surged nearly 7% in pre-market trading on Tuesday, after the biopharmaceutical company announced that it expects to achieve positive operating income for the full year 2025 in accordance with US GAAP (Generally Accepted Accounting Principles).\nThe encouraging forecast from BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative cancer medicines, sent a positive signal to investors and sparked a rally in the company's stock. Shares were up 4% in Hong Kong and 4% in Shanghai during Tuesday morning trading session.\nBeiGene's projection of positive operating income for 2025 reflects the company's progress and growth prospects in the oncology market. As a leading player in the development of innovative cancer treatments, the company's strong financial performance and positive outlook have fueled investor confidence, driving the stock's upward momentum.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}